Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

New radionuclide-labeled targeting nanocarrier systems have generated new opportunities for tumor treatment and imaging. Nevertheless, such therapeutic strategy is clinically unfeasible on anaplastic thyroid carcinoma (ATC) patients, because of lacking suitable targets and resistance to radiation. In order to figure out a potential treatment, immuno-histochemical staining is performed in human ATC tissue species and high expression of cluster determinant 44 (CD44) is found. Therefore, a CD44-targeted delivery system is designed and constructed by self-assembly of tyrosine (Tyr)-hyaluronic acid (HA)-polyethyleneimine (PEI), which can radiolabel 131/125 I and load a p53 mutant restoring regent, Prima-1. The 125 I-labeled nanocomposites display an impressive tumor imaging as well as a long radiation treatment cycle. The 131 I-labeled nanoparticles show remarkable anti ATC-tumor effects in vitro and in vivo, due to radiosensitization of Prima-1 by reactivation of the p53 mutants. © 2020 Wiley-VCH GmbH.


Shuo Huang, Linlin Zhang, Miaomiao Xu, Chao Li, Hongliang Fu, Jie Huang, Xin Jin, Sheng Liang, Hui Wang. Co-Delivery of 131 I and Prima-1 by Self-Assembled CD44-Targeted Nanoparticles for Anaplastic Thyroid Carcinoma Theranostics. Advanced healthcare materials. 2021 Feb;10(3):e2001029

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 33326188

View Full Text